NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Eton Pharmaceuticals Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.
Eton Pharmaceuticals develops and sells treatments for rare diseases. The company markets eight approved products in endocrinology and metabolic conditions through specialty pharmacies in the United States. Eton also maintains five experimental product candidates in late-stage development for various pediatric and inherited disorders.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Eton Pharmaceuticals Inc stock.
Overvalued: intrinsic value $8.19 per share, market price $52.18, margin of safety -537.5% (as of 2026-10-30).
A 2.2x revenue multiple, discounted for its losses, values the shares at $8.19; the price of $52.18 is 537% above that value.
Leak Score: 37/100 on 11 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
33 more in this industry show a wider margin of safety.
ETON is overvalued (as of the 2026-10-30 close). A 2.2x revenue multiple, discounted for its losses, values the shares at $8.19; the price of $52.18 is 537% above that value.
$8.19 per share (as of the 2026-10-30 close), against a market price of $52.18. That is a margin of safety of -537.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
37 out of 100, which we rate "On Watch", on 11 of 12 value investing signals.